## **REMARKS**

Applicants wish to thank the Examiner for the allowance of claims 1, 3, 4, 11-26, and 28 and for the indication that claims 2, 5-8, 10, and 27 would be allowed if rewritten to overcome the Section 112 rejections. Applicants have amended the specification and claims 2, 5-8, 10, and 27 in a manner that should obviate the Section 112 rejections and the objection regarding the specification.

Claims 6, 7, and 27 were rejected under 35 U.S.C. 112, first paragraph. The Examiner states that it is not clear what substituent is represented by the term "ocxazinly". Applicants appreciate the Examiner pointing out this typographical error. The term should be "oxazinyl", and the claims have been amended to correct this error.

Claims 2, 5-10, and 27 were rejected under 35 U.S.C. 112, second paragraph.

Applicants have amended these claims in a manner which should overcome this rejection.

It is believed that these changes now make the claims clear and definite and, if there are any problems with these changes, Applicants' attorney would appreciate a telephone call.

In light of the above amendments and remarks, Applicants respectfully request that the amended claims allowed.

Respectfully submitted,

Sarah Meeks Roberts Attorney for Applicants

Registration No. 33,447

SMR:mec

Rochester, New York 14650-2201

Phone: (585) 588-7488 Facsimile: (585) 477-1148